Guangzhou JOYO Pharma Co., Ltd
13
5
5
6
Key Highlights
Risk & Performance
Pipeline Risk Assessment
Pipeline Risk Assessment
Based on historical performance
Moderate Risk
Score: 45/100
0.0%
0 terminated/withdrawn out of 13 trials
100.0%
+13.5% vs industry average
8%
1 trials in Phase 3/4
0%
0 of 6 completed trials have results
Key Signals
Enrollment Performance
Analytics
Activity Timeline
Global Presence
Clinical Trials (13)
Study of JYP0015 in Patients With Advanced Solid Tumors Harboring Specific Mutations in RAS
Role: lead
JYP0322 Versus Platinum Based Doublet Chemotherapy in ROS1 Positive Patients Previously Treated With ROS1-TKIs.
Role: lead
Ascending-Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics of DC371739 Single-Dose Treatment in Healthy Subjects
Role: lead
Phase I Study of JYP0322 in ROS1 Fusion-Positive Solid Tumors
Role: lead
A Study to Evaluate JYP0061 Tablets in Patients With Moderate-to-severe Atopic Dermatitis
Role: lead
A Study to Evaluate the Efficacy and Safety of JYP0061 in Patients With Acute Neuromyelitis Spectrum Disease (NMOSD)
Role: lead
The Safety, Tolerability, and Pharmacokinetic Study of SC1011 in Healthy Subjects.
Role: lead
SC1011 Twice Daily vs Placebo in Patients Diagnosed With Idiopathic Pulmonary Fibrosis (IPF)
Role: lead
A Clinical Trial Evaluating JYP0035 Capsule Monotherapy in Patients With Advanced Solid Tumors
Role: collaborator
Evaluation of Safety, Tolerability, PK/PD, and Metabolism of Single-Dose Singletine(DC407) in Adults
Role: lead
Evaluation of Safety, Tolerability & Pharmacokinetics of JYP0061 in Healthy Adults.
Role: lead
Safety, Tolerability and Pharmacokinetic Study of SC1011 in Healthy Subjects
Role: lead
Multiple Ascending Dose Study to Evaluate the Safety, Tolerability of DC371739 Treatment in Hypercholesterolemic
Role: lead
All 13 trials loaded